* allergy to hydroxychloroquine or azithromycin * history of bone marrow transplant * known g6pd deficiency * chronic hemodialysis or glomerular filtration rate \< 20ml/min * psoriasis * porphyria * concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone, cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol * known history of long qt syndrome * current known qtc\>500 msec * pregnant or nursing * prisoner * weight \< 35kg * seizure disorder * severe liver disease * outpatient use of hydroxychloroquine for treatment of a disease other than covid-19 or has received more than 2 days of hydroxychloroquine or azithromycin for suspected or confirmed covid-19 * patient has recovered from covid-19 and/or is being discharged from the hospital on day of enrollment. * treating physician refuses to allow patient participation in the study * unable to obtain informed consent * prior enrollment in this study

* allergy to hydroxychloroquine or azithromycin * history of bone marrow transplant * known g6pd deficiency * chronic hemodialysis or glomerular filtration rate \< 20ml/min * psoriasis * porphyria * concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone, cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol * known history of long qt syndrome * current known qtc\>500 msec * pregnant or nursing * prisoner * weight \< 35kg * seizure disorder * severe liver disease * outpatient use of hydroxychloroquine for treatment of a disease other than covid-19 or has received more than 2 days of hydroxychloroquine or azithromycin for suspected or confirmed covid-19 * patient has recovered from covid-19 and/or is being discharged from the hospital on day of enrollment. * treating physician refuses to allow patient participation in the study * unable to obtain informed consent * prior enrollment in this study

- allergy to hydroxychloroquine or azithromycin - history of bone marrow transplant - known g6pd deficiency - chronic hemodialysis or glomerular filtration rate < 20ml/min - psoriasis - porphyria - concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone, cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol - known history of long qt syndrome - current known qtc>500 msec - pregnant or nursing - prisoner - weight < 35kg - seizure disorder - severe liver disease - outpatient use of hydroxychloroquine for treatment of a disease other than covid-19 or has received more than 2 days of hydroxychloroquine or azithromycin for suspected or confirmed covid-19 - patient has recovered from covid-19 and/or is being discharged from the hospital on day of enrollment. - treating physician refuses to allow patient participation in the study - unable to obtain informed consent - prior enrollment in this study

- allergy to hydroxychloroquine or azithromycin - history of bone marrow transplant - known g6pd deficiency - chronic hemodialysis or glomerular filtration rate < 20ml/min - psoriasis - porphyria - concomitant use of digitalis, flecainide, amiodarone, procainamide, propafenone, cimetidine, dofetilide, phenobarbital, phenytoin, or sotalol - known history of long qt syndrome - current known qtc>500 msec - pregnant or nursing - prisoner - weight < 35kg - seizure disorder - severe liver disease - outpatient use of hydroxychloroquine for treatment of a disease other than covid-19 or has received more than 2 days of hydroxychloroquine or azithromycin for suspected or confirmed covid-19 - patient has recovered from covid-19 and/or is being discharged from the hospital on day of enrollment. - treating physician refuses to allow patient participation in the study - unable to obtain informed consent - prior enrollment in this study